A Phase I Clinical Study, Randomized, Double-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability, and Population Pharmacokinetics of LCB01-0371 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2018
Price : $35 *
At a glance
- Drugs Delpazolid (Primary)
- Indications Methicillin-resistant Staphylococcus aureus infections; Tuberculosis; Vancomycin-resistant enterococcal infections
- Focus Adverse reactions
- Sponsors LegoChem Biosciences
- 09 Nov 2018 Results assessing safety and tolerability published in the Clinical Therapeutics.
- 16 Nov 2014 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 06 May 2013 New trial record